Issued Patents All Time
Showing 1–25 of 51 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12364697 | G1T38 superior dosage regimes | Andrew Beelen | 2025-07-22 |
| 12312360 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | — | 2025-05-27 |
| 12285431 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | John Emerson Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino | 2025-04-29 |
| 12168666 | Morphic forms of trilaciclib and methods of manufacture thereof | Stephen E. Schneider, Alexander Smith, Hannah S. White, Jaroslaw Mazurek | 2024-12-17 |
| 11717523 | Transient protection of normal cells during chemotherapy | John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares | 2023-08-08 |
| 11654148 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares | 2023-05-23 |
| 11643416 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | — | 2023-05-09 |
| 11529352 | Preservation of immune response during chemotherapy regimens | Jessica A. Sorrentino, Anne Lai, Patrick Joseph Roberts | 2022-12-20 |
| 11446295 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | John Emerson Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White | 2022-09-20 |
| 11395821 | Treatment of EGFR-driven cancer with fewer side effects | Jessica A. Sorrentino, John Emerson Bisi, Andrew Beelen | 2022-07-26 |
| 11364222 | Combination therapy for treatment of cancer | Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti | 2022-06-21 |
| 11357779 | G1T38 superior dosage regimes | Andrew Beelen | 2022-06-14 |
| 11090306 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | John Emerson Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino | 2021-08-17 |
| 11040042 | Transient protection of normal cells during chemotherapy | John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares | 2021-06-22 |
| 10988479 | Morphic forms of trilaciclib and methods of manufacture thereof | Stephen E. Schneider, Alexander Smith, Hannah S. White, Jaroslaw Mazurek | 2021-04-27 |
| 10981887 | Benzothiophene estrogen receptor modulators | — | 2021-04-20 |
| 10966984 | Transient protection of normal cells during chemotherapy | John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares | 2021-04-06 |
| 10927120 | CDK inhibitors | Francis Xavier Tavares | 2021-02-23 |
| 10925878 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares | 2021-02-23 |
| 10829490 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | David Kendall Jung | 2020-11-10 |
| 10709711 | Highly active anti-neoplastic and anti-proliferative agents | John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares | 2020-07-14 |
| 10696682 | CDK inhibitors | Francis Xavier Tavares | 2020-06-30 |
| 10660896 | Transient protection of normal cells during chemotherapy | John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares | 2020-05-26 |
| 10654831 | Antiproliferative pyrimidine-based compounds | Ricky D. Gaston, Robert C. Gadwood | 2020-05-19 |
| 10633362 | Benzothiophene estrogen receptor modulators | — | 2020-04-28 |